Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.
Opinion: Assemblyman Gary Schaer on ‘A Blueprint for Tomorrow’
Asm. Gary Schaer
Trenton, NJ, June 20, 2017 — Assemblyman Gary S. Schaer (D-Passaic), Chair of the Assembly Budget Committee, last month shared the following with Innovation New Jersey readers:
Each time we tackle the state budget, we are reminded that it is a living, breathing document that, at its core, should fundamentally reflect our priorities. As we enter final deliberations in crafting this year’s state budget, that reminder is all the more potent.
One of the reasons New Jersey’s economy lagged far behind most of the nation after the Great Recession is because we failed to make the proper investments to capitalize on our strengths and leverage our assets to grow our economy. We cannot expect to move forward and grow as a state without planting the proper seeds. Continue reading
Ex-Roche Campus Reinvented as ‘On3’ Science Center
Nutley, NJ, June 20, 2017 — Owen Proctor reports in The Record/NorthJersey.com that the flagship project for the campus is a medical school that is a joint plan of Hackensack Meridian Health and Seton Hall University, and would be the state’s first private medical school in 50 years.
The New Jersey Economic Development Authority (NJEDA) has approved $16.9 million in tax credits to develop the site.
In discussing the formation of a bio sciences campus, Diaz cited Silicon Valley and Cambridge, Mass., where such “eco-systems” exist. “Sort of like, where there’s a McDonald’s, there’s a Burger King,” Diaz said. Continue reading
Opinion: Former Merck CEO and Princeton University President Emeritus on ‘Trump’s War on Science Threatens U.S. Prosperity’
Princeton, NJ, June 12, 2017 — Roy Vagelos, retired Chairman and CEO of Merck & Co. and Chairman of the Board of Regeneron Pharmaceuticals, and Shirley Tilghman, President Emeritus of Princeton University and a professor of Molecular Biology and Public Affairs, published the following opinion piece in The Star-Ledger on June 6:
In the past 40 years, the U.S. has been the world leader in converting fundamental scientific discoveries into innovative new treatments for life-threatening disease. New drugs, vaccines, and medical devices have improved human health and increased our lifespan. Continue reading
HINJ to Serve as Lead Sponsor of Choose New Jersey’s Annual Reception at BIO International on June 19 in San Diego
New Brunswick, NJ, May 19, 2016 — The HealthCare Institute of New Jersey (HINJ) will serve, once again, as the lead sponsor of Choose New Jersey’s annual reception at BIO International Convention on Monday, June 19 from 5:00 to 7:00 p.m. at Top of the Hyatt at the Grand Hyatt San Diego.
Choose New Jersey will showcase top life sciences companies, universities, trade associations, the State government at its New Jersey Pavilion (Booth #1737) at BIO International 2017, which will be held from June 19 to 22 at the San Diego Convention Center. Continue reading
Biopharmaceutical Companies Unveil Latest GoBOLDLY TV Ad Showcasing ‘New World’ of Medicine
Washington, DC, May 17, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) on May 15 unveiled its latest advertisement as part of its groundbreaking GOBOLDLY™ campaign, titled “New World, “featuring some of the most extraordinary breakthroughs in science being discovered by biopharmaceutical researchers.
“Biopharmaceutical researchers are driving unimaginable innovation in science, which is revolutionizing how the most complex diseases are treated,” said Stephen J. Ubl, president and chief executive officer of PhRMA.
“We truly are in a new world of medicine and on the verge of something even greater and more impactful. This promises a future with endless potential of scientific advances.” Continue reading
Study: Life Sciences Industry Still Lack Gender Diversity at the Executive C-Suite Level
New York, NY, May 11, 2017 — New research released on April 20 by Epsen Fuller Group|IMD, an executive search and leadership consulting firm, reveals the severity of the gender gap in the boardroom and C-Suite in the life science community — including the pharmaceutical, biotechnology and medical devices sectors — across 423 publicly held life science companies throughout the U.S., ranging in size from micro-cap to large-cap.
This is an important study in that, while most widely published studies on gender diversity in the corporate world focus only on the Fortune 500, FTSE 100, or other lists of exclusively mega-sized enterprises, Epsen Fuller’s study represents a broad cross-section of company size, as defined by market capitalization, in a specific industry sector. Continue reading
BioCurrent Technologies Wins ‘Best in Show’ at 1st Pitch Life Science Competition New Jersey
Piscataway, NJ, May 1, 2017 — Mid-Atlantic Bio Angels (MABA) announced that BioCurrent Technologies (BioCurrent), a microbe-based, sustainable nanomaterials company, was named “Best in Show” by the audience and “Most Fundable” by the investor panel at MABA’s 1st Pitch Life Science New Jersey event held on April 18, 2017 at Rutgers University in Piscataway, N.J.
“We were very excited to be selected for 1st Pitch Life Science and even more excited to have been selected as both Best in Show and Most Fundable.
“We learned a lot from both the excellent panel as well as the thoughtful questions from the audience, and are grateful to our team, including David Howard and Matthew Chiusano from Ramapo College, who helped us develop our presentation,” said Mark Miller, CEO of BioCurrent. Continue reading
Study: Life Sciences Still Lack Gender Diversity at the Top
New York, NY, April 24, 2017 — New research released on April 20 by Epsen Fuller Group|IMD, a Top-20 executive search and leadership consulting firm, reveals the severity of the Gender Gap in the Boardroom and C-Suite in the Life Science sector — Pharmaceutical, Biotech & Medical Devices — across 423 publicly held Life Science companies throughout the US, ranging in size from Micro-cap to Large-cap.
This is an important study in that, while most widely published studies on gender diversity in the corporate world focus only on the Fortune 500, FTSE 100, or other lists of exclusively mega-sized enterprises, Epsen Fuller’s study represents a broad cross-section of company size, as defined by market capitalization, in a specific industry sector. Continue reading
Deloitte Report: Driving Medical Innovation Through Biopharmaceutical Collaboration.
Washington, DC, April 18, 2017 — Emma Van Hook, a director of Policy & Research at the Pharmaceutical Research and Manufacturers of America (PhRMA), reports on The Catalyst that a new report from Deloitte examines the changing landscape of biopharmaceutical research, as stakeholders across the research and development (R&D) ecosystem are increasingly coming together to tackle sciences’ most vexing health challenges.
The new research illustrates there has been a significant shift in recent years from traditional, asset-based or transactional agreements to more open, collaborative approaches for conducting biopharmaceutical research.
Deloitte compiled and analyzed a database of thousands of partnerships initiated between 1995 and 2014. Continue reading
Governor Christie Signs Proclamation Announcing March as ‘New Jersey Life Sciences Month’
Trenton, NJ, April 9, 2017 — BioNJ announced that Governor Chris Christie had declared March 2017 as New Jersey Life Sciences Month.
Life Sciences Month was established to raise awareness of the robust medical innovation taking place in New Jersey and highlights the important impact that the industry has on New Jersey’s economy.
Click here to view Governor Christie’s signed Proclamation. Continue reading
